The recent surge in biotech stocks extends beyond IPOs, as investors chase companies working on potential vaccines to combat Covid-19. But some longtime investors are wary of the run-up and warn there are risks to chasing companies at early stages of development.
The recent surge in biotech stocks extends beyond IPOs, as investors chase companies working on potential vaccines to combat Covid-19. But some longtime investors are wary of the run-up and warn there are risks to chasing companies at early stages of development.
Share this Article
Comment on this Article
Recommended
Please to comment